(Q34480446)

2 August 2017

The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial (English)

1 reference

2 August 2017

0 references

14

1 reference

2 August 2017

Helen K Reddel

9

0 references

Robert Niven

Robert Niven

7

0 references

Peter Wark

Peter Wark

5

0 references

Stephen T. Holgate

15

Stephen T Holgate

1 reference

2 August 2017

Donna E Davies

10

0 references

Sebastian L Johnston

Sebastian L Johnston

3

0 references

author name string

Ratko Djukanović

1

1 reference

2 August 2017

Tim Harrison

2

1 reference

2 August 2017

Flic Gabbay

4

1 reference

2 August 2017

Neil C Thomson

6

1 reference

2 August 2017

Dave Singh

8

1 reference

2 August 2017

Richard Marsden

11

1 reference

2 August 2017

Christine Boxall

12

1 reference

2 August 2017

Sarah Dudley

13

1 reference

2 August 2017

Phillip Monk

16

1 reference

2 August 2017

INTERCIA Study Group

17

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

American Journal of Respiratory and Critical Care Medicine

2 August 2017

1 reference

2 August 2017

190

1 reference

2 August 2017

2

1 reference

2 August 2017

145-154

1 reference

Impaired innate interferon induction in severe therapy resistant atopic asthmatic children

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

The role of viruses in acute exacerbations of asthma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Decreased activation of inflammatory networks during acute asthma exacerbations is associated with chronic airflow obstruction

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Predicting worsening asthma control following the common cold

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Global strategy for asthma management and prevention: GINA executive summary.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226052

Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study.

6 July 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Rhinovirus-induced interferon production is not deficient in well controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

British Guideline on the Management of Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Simple procedures for blinded sample size adjustment that do not affect the type I error rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Costs of asthma according to the degree of severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Role of deficient type III interferon-λ production in asthma exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201312-2235OC

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

21 January 2018

1 reference

12 December 2020

The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis

1 reference

12 December 2020

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

1 reference

12 December 2020

The asthma index: a continuous variable to characterize exacerbations of asthma

1 reference

12 December 2020

10.1164/RCCM.201312-2235OC

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference